Bevacizumab offers modest benefit to patients with advanced breast cancer, either as a first- or second-line therapy, according to a Cochrane review published online this week (Cochrane Database of Systematic Reviews 2012 Issue 7, 11 July 2012).
The review analysed seven trials, including a total of 4,032 patients, and found that the benefit of bevacizumab use was limited to prolonging progression-free survival. No increase in overall survival or quality of life was observed.
?
?
?
Source: http://www.pjonline.com/news/cochrane_view_of_bevacizumab
the muppets percy harvin percy harvin best cyber monday deals best cyber monday deals cyber monday grover norquist
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.